This study aims to evaluate the diagnostic potential of urinary CX3CL1 levels in distinguishing between AD patients, those experiencing amnestic mild cognitive impairment (aMCI), and cognitively normal (CN) individuals. This evidence concerns the gene CX3CL1 and Alzheimer disease.